Modulators of cystic fibrosis transmembrane conductance regulator
US-2018185364-A1 · Jul 5, 2018 · US
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators, pharmaceutical compositions, and uses thereof
US12465595B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12465595-B2 |
| Application number | US-202118018997-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 30, 2021 |
| Priority date | Jul 31, 2020 |
| Publication date | Nov 11, 2025 |
| Grant date | Nov 11, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in need thereof.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound that is 3-(2-bromo-5-methoxyphenyl)-6-isopropyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine or a salt thereof. 2 . A method of treating cystic fibrosis or rhinosinusitis comprising administering to a subject in need thereof an effective amount of a compound of claim 1 . 3 . The method of claim 2 , further comprising administering ivacaftor, lumacaftor, tezacaftor, elexacaftor, or combinations thereof. 4 . A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant, and/or excipient. 5 . The composition of claim 4 , further comprising ivacaftor, lumacaftor, tezacaftor, elexacaftor, or combinations thereof. 6 . The method of claim 2 , wherein the method comprises treating cystic fibrosis. 7 . The method of claim 2 , wherein the method comprises treating rhinosinusitis.
Assignees
Inventors
Classifications
Thidiazoles · CPC title
non condensed and containing further heterocyclic rings · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
- A61K31/427Primary
not condensed and containing further heterocyclic rings · CPC title
1,3-Thiazoles · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12465595B2 cover?
- This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managing a CFTR related disease or condition or respiratory distress comprising administering an effective amount of a CFTR modulator disclosed herein to a subject in…
- Who is the assignee on this patent?
- Univ Emory, Childrens Healthcare Atlanta Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/427. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).